8-K: BioRestorative Therapies Faces Nasdaq Delinquency Notice

BioRestorative Therapies, Inc. received a delinquency notification from Nasdaq for failing to file its Q2 2026 financial report, risking its listing.

Summary

• BioRestorative Therapies, Inc. (BRTX) received a delinquency notification from Nasdaq on August 21, 2026.
• The notification is due to the company's failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2026.
• This non-compliance violates Nasdaq Listing Rule 5250(c)(1).
• The company has until October 20, 2026, to submit a plan to regain compliance.
• If the plan is accepted, the company may have up to 180 days (until February 16, 2027) to regain compliance.
• Failure to regain compliance could lead to delisting from the Nasdaq Capital Market.
• The company is actively working to complete the Form 10-Q and develop a compliance plan.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the company's non-compliance with Nasdaq listing rules and the potential risk of delisting.

Positives

• The Nasdaq notice has no immediate effect on the listing of the company's common stock.
• The company has a defined period (until October 20, 2026) to submit a plan to regain compliance.
• A potential extension of up to 180 days is available if the compliance plan is accepted.

Negatives

• The company is not in compliance with Nasdaq's requirement to file periodic financial reports on time.
• There is a risk of delisting from the Nasdaq Capital Market if compliance is not regained.
• The delay in filing the Form 10-Q indicates potential internal operational or financial reporting challenges.

Risks

• Potential delisting from the Nasdaq Capital Market if the company fails to regain compliance.
• Nasdaqs potential rejection of the compliance plan, leading to further action.
• The possibility that the company's common stock could be delisted if compliance is not achieved within the prescribed period or any granted extension.
• Risks associated with the company's ability to complete its financial statements and related disclosures in a timely manner.
• Availability of internal and external resources necessary to prepare and file the Form 10-Q.

Future Outlook

The company is working to complete and file its Form 10-Q and submit a plan to Nasdaq to regain compliance with listing rules. The outcome of this process, including Nasdaq's acceptance of the plan and the company's ability to meet compliance deadlines, will determine its continued listing status.

Management Comments

• The Company is working prudently to complete and file the Form 10-Q and submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).

Industry Context

StockSavvy.ai notes that timely financial reporting is a fundamental requirement for maintaining a listing on major exchanges like Nasdaq. Failure to do so, as seen here, can trigger significant scrutiny and increase the risk of delisting, impacting investor confidence and liquidity.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to increased risk of delisting and reduced investor confidence. Liquidity may also be affected if delisted.
• Creditors: May face increased risk if the company's financial stability is questioned due to reporting issues.
• Employees: Uncertainty regarding the company's future stability and operations.

Next Steps

• Complete and file the Form 10-Q for the quarterly period ended June 30, 2026.
• Submit a plan to Nasdaq by October 20, 2026, to regain compliance with listing rules.
• Work towards regaining compliance with Nasdaq Listing Rule 5250(c)(1) within the prescribed timeframe or any granted extension.

Key Dates

Recommendation

The filing indicates a significant compliance issue with Nasdaq, raising concerns about the company's operational stability and potential delisting. While the company is actively addressing the issue, the uncertainty warrants a cautious 'hold' stance until compliance is regained and the financial reporting process is stabilized.

Keywords

Nasdaq Delinquency, Form 10-Q, Listing Rule Violation, Compliance Plan, Delisting Risk, Financial Reporting, BioRestorative Therapies